Digital necrosis induced by erlotinib treatment in metastatic adenocarcinoma of the lung and anti-Scl-70 antibodies were positive. Our patient scored 7 according to the Naranjo adverse drug reaction algorithm 1 (0 = doubtful; 1-4 = possible; 5-8 = probable; 9 = highly probable), and the hypothesis of a cause-effect relationship is therefore plausible.
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We read with interest the article by HuseinElAhmed et al., who reported the onset of severe Raynaud syndrome induced by adjuvant interferon alfa in a woman who underwent surgery for cutaneous ulcerated nodular melanoma, with evolution to pelvic lymph node metastasis. This patient had a previously undiagnosed scleroderma.
Here, we report a similar experience in a woman with adenocarcinoma of the lung. She developed upper-limb digital necrosis after the start of secondline treatment with erlotinib, an oral anticancer drug that inhibits the epidermal growth factor receptor.
Our patient, a 72-year-old non-smoking woman with hypertension, has metastatic lung cancer progressing even after 3 cycles of chemotherapy with carboplatin and gemcitabine. At 20 days after the start of oral erlotinib 150 mg daily, she presented to our clinic for the onset of digital necrosis at the second finger of the right hand (Figure 1) .
Erlotinib was promptly discontinued, and treatment with calcium channel blockers, nitrates, and antiplatelet drugs was initiated. After 3 weeks of therapy, the digital lesion was completely healed. As in the case of the patient described by Husein-ElAhmed et al., our patient had an unrecognized scleroderma. Her medical history included Raynaud phenomenon, physical examination showed acrosclerosis and teleangiectasia, figure 1 Appearance of digital necrosis after start of erlotinib therapy.
